The prebiotic landscape: history, health and physiological benefits, and regulatory challenges - an IPA perspective part 1.

Prebiotics are becoming increasingly recognized by consumers, health care professionals and regulators as important contributors to health. Nonetheless, the development, progress, and adoption of prebiotics is hindered by loose terminology, various misconceptions about sources and types of compounds that may be classified as prebiotics, and the lack of consensus on a definition that satisfies regulators. Evolving knowledge of the microbiome and its effects on host health has generated opportunities for modulation of the microbiota that can support host health.

Changes in the phenotypic susceptibility of isolates to macrolide antimicrobials during the early feeding period following metaphylactic tulathromycin use in western Canadian feedlot calves.

Cattle at high-risk for bovine respiratory disease on entry to western Canadian feedlots are often treated metaphylactically with antimicrobials from the macrolide class. High levels of resistance to macrolides have been reported in isolates from clinical samples, but it is less clear whether this trend extends to the broader feedlot population. The objective was to describe near-term [< 40 days on feed (DOF)] changes in the recovery and susceptibility of isolates from healthy feedlot calves after metaphylactic exposure to tulathromycin.

Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon.

About 20% to 30% of pediatric patients with immune thrombocytopenia (ITP) develop chronic or refractory disease lasting 12 months or more that can be challenging to treat. Eltrombopag is being used after failure of previous lines of therapy with good results at tertiary healthcare centers in Lebanon, a developing country with available multidisciplinary treatment modalities. This is a retrospective multicenter observational study that analyzed data on pediatric patients with chronic or refractory ITP who were given eltrombopag as second- or third-line therapy in 6 large referral hospitals in Beirut (country capital located in mid Lebanon), South, North, and Mount Lebanon between October 2016 and May 2020.